Get the Stockscreener App
919.77
3.74%
33.14
Pre-market:
924.78
5.01
+0.54%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $919.77, with a volume of 3.46M.
It is up +3.74% in the last 24 hours and down -12.57% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$886.63
Open:
$893.49
24h Volume:
3.46M
Relative Volume:
1.15
Market Cap:
$821.68B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
40.72
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
+1.85%
1M Performance:
-12.57%
6M Performance:
+20.55%
1Y Performance:
+11.36%
1-Day Range:
$892.14
$924.14
1-Week Range:
$877.11
$924.14
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
919.77 | 821.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.44 | 588.76B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.49 | 384.69B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
197.22 | 305.86B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.29 | 297.40B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Donaldson Capital Management LLC Has $72.98 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Carlsquare/Vontobel weekly trading note: Eli Lilly has reached a crossroads - TradingView
Weight-Loss Drug Giant Eli Lilly Bets Big Again. Spending $7.8 Billion to Acquire Centessa, Is Now a Good Time to Buy Eli Lilly? - TradingKey
Eli Lilly & Co. Stock: Centessa Acquisition Signals Bold Expansion into Sleep Disorder Treatments Am - AD HOC NEWS
Lilly to acquire Centessa for OX2R sleep disorder drugs - Investing.com
Lilly to acquire Centessa for OX2R sleep disorder drugs By Investing.com - Investing.com India
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly - The Manila Times
Eli Lilly to Acquire Centessa Pharmaceuticals in Cash Deal - TipRanks
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly - Benzinga
Lilly expands neuroscience portfolio with Centessa acquisition - WISH-TV
Eli Lilly to acquire Centessa in deal for treatment of sleep-wake disorders - mlex.com
Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy - BioWorld MedTech
Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.6%What's Next? - MarketBeat
Eli Lilly inks USD$2.75B AI drug deal with Insilico Medicine - Mugglehead Investment Magazine
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition - MedCity News
Eli Lilly to Acquire Centessa in Up to $7.8 Billion Deal, 70% Premium - TradingView
Lilly (NYSE: LLY) buying Centessa (NASDAQ: CNTA) for $38 plus CVR - Stock Titan
Eli Lilly and Co Stock Gains on Centessa Acquisition and Strong Q4 Results Amid Obesity Drug Momentu - AD HOC NEWS
Lilly Buys Sleep Disorders Drugmaker For Up To $7.8 Billion - Investor's Business Daily
Eli Lilly and Company (NYSE:LLY) Moves Within Russell 1000 Index Landscape - Kalkine Media
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout - Finviz
Lilly Acquires Centessa for Up to $7.8B; Biogen Buys Apellis for Up to $6.1B - Genetic Engineering and Biotechnology News
Eli Lilly announces $7 billion merger, with eye on wakefulness drugs - Terre Haute Tribune-Star
Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion - The New York Times
Lilly to buy narcolepsy drug developer for $6.3 billion - C&EN
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,296 - moomoo.com
Eli Lilly announces $7-billion merger, with eye on wakefulness drugs - WFYI
Eli Lilly Bets €2.4B on AI-Designed Drugs in New Insilico Medicine Deal - Oncodaily
Lilly: $6.3 Billion Acquisition Of Centessa Pharmaceuticals To Expand Sleep Disorder Pipeline - Pulse 2.0
Eli Lilly (LLY) Acquisition Sparks Biotech Market Optimism - GuruFocus
Kirkland, Goodwin Steer Lilly's $7.8B 'Sleep-Wake' Disorder Deal - Law360
Barclays reiterates Eli Lilly stock Overweight on acquisition - Investing.com
Eli Lilly (LLY) Plans $6.3 Billion Acquisition of Centessa - GuruFocus
Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B deal - statnews.com
Eli Lilly's Centessa Deal Shows It Is Awake To New Narcolepsy Reality (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) to Acquire Centessa in $7.8 Billion Deal - GuruFocus
Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout - BioPharma Dive
Pharma giant snags Boston-area biotech for $6.3B amid sleep medicine push - The Business Journals
Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet - Reuters
Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B - dailyjournal.net
Eli Lilly & Insilico: How Generative AI can Transform Pharma - Healthcare Digital
Centessa shares soar after Lilly announces multibillion-dollar acquisition deal - MSN
Nvidia invests $2B in Marvell, Eli Lilly to buy drugmaker Centessa - Yahoo Finance
New Indianapolis downtown basketball court to be built by Clark Foundation, Eli Lilly and Co. - dailyjournal.net
Lilly to acquire UK company developing treatments for sleep disorders - Fox 59
Eli Lilly to buy Centessa Pharmaceuticals for up to $7.8bn - sharecast.com
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8B in Sleep Drug Mega-Deal, CNTA Stock Soaring 45% - International Business Times Australia
Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3 billion deal - The Boston Globe
Eli Lilly Expands Into Sleep Medicine With Centessa BuyoutCentessa Pharmaceuticals (NASDAQ:CNTA), Eli - Benzinga
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs - cnbc.com
BMO reiterates Eli Lilly stock Outperform on Centessa acquisition - Investing.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):